Health
Moderna doses first patients in COVID-19 vaccine booster trial – The Science Board
Moderna has dosed the first patients in its study of modified COVID-19 vaccines, designed to address the potential need for vaccine booster candidates.
The new candidate, messenger RNA (mRNA)-1273.351, encodes the prefusion stabilized spike protein of the SARS-CoV-2 variant B.1.351, first identified in South Africa, and is being assessed as a booster vaccine to increase the response to emerging SARS-CoV-2 variants. The company is also investigating a second, multivalent candidate, mRNA-1273.211, that is a combination of mRNA-1273 and mRNA-1273.351.
Through a phase II clinical trial amendment, the company will enroll 60 participants previously vaccinated…
-
General22 hours agoMichael Beatty, veteran current affairs journalist and animal welfare advocate, dies aged 76
-
Noosa News15 hours ago‘Sunny, benign’ school holiday weather after morning showers in parts of Queensland
-
Noosa News12 hours agoTips to improve engagement – Proctor
-
Business16 hours agoWhy is Alphabet stock worth less than Nvidia, Microsoft, Apple, and Amazon even though it is the most profitable S&P 500 company?